Zouina Sarfraz: Presenting New Studies on Melanoma and Lung Cancer Brain Metastases at SNO 2026
Zouina Sarfraz / LinkedIn

Zouina Sarfraz: Presenting New Studies on Melanoma and Lung Cancer Brain Metastases at SNO 2026

Zouina Sarfraz, Research Fellow in Medical Oncology at Baptist Health Herbert Wertheim Cancer Institute, shared on LinkedIn:

“SNO 2026 was a particularly meaningful milestone in my research journey, with 1 full oral presentation, 6 rapid orals, and 12 posters at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia.

None of this would have been possible without the exceptional mentorship of Dr. Manmeet Ahluwalia. His scientific vision, unwavering support, and commitment to promoting meaningful collaborations have been instrumental in shaping my development as an investigator.

A personal highlight for me was presenting ‘ORBIT-MBM: Outcomes Related to BRAF/MEK and Immunotherapy Timing in Melanoma Brain Metastases – Does Timing Influence Survival?‘ during the CNS Metastases Oral Abstracts Session.

Our study explored whether the timing of BRAF/MEK-targeted therapy relative to immunotherapy influences survival in patients with melanoma brain metastases. As treatment options continue to evolve, understanding optimal therapeutic sequencing remains an important clinical question.

Thank you to Dr. Morgan Freret and Dr. Michelle Kim for moderating the session and facilitating an engaging scientific discussion.

Another highlight for me was the selection of six of our studies for rapid oral presentations, including five on which I was first author. These explored treatment sequencing and survival in melanoma brain metastases, targeted therapy and prognostic modeling in NSCLC-BM, the intracranial activity and neurologic safety of tarlatamab in SCLC-BM, blood-brain barrier dysfunction and post-radiosurgical toxicity, and gender/geographic representation in SNO Annual Meetings.

I am also grateful to Dr. Tulika Ranjan and Dr. Youngsoo Rho for the opportunity to collaborate on additional research featured in the CNS Metastases Oral Abstracts Session.

My sincere thanks to our collaborators: Fatma Nihan Akkoç Mustafayev, Lydia Hodgson, Andrea McCracken, Charles Hurmiz, Suresh Marada, Matthew Shepard, Sankalp Das, Arpa Dilanchian, Maria Tabares, Logan Spiegelman, Kevin Vazquez, Tanay Malla, Abeer S, Rupesh Kotecha, Matthew D. Hall, Azza Sarfraz, Namita Ruhela, Ruchit Jain, Sonikpreet Aulakh and others for their contributions to our collective research efforts.

I would also be remiss not to acknowledge Valerie Bethel, Candice Schottenloher, and Laura Horna for their invaluable administrative and organizational support in making these efforts possible.

Beyond the presentations, what I value most about SNO is the opportunity to exchange ideas, learn from colleagues, and return with new questions worth investigating.

Grateful to represent Baptist Health Herbert Wertheim Cancer Institute and to everyone who contributed to these collaborative efforts.”

Zouina Sarfraz

About SNO 2026

The 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO 2026) took place from November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Under the theme ‘Crossing the Translational Divide: From Neurons to Novel Therapies,’ the congress brought together more than 3,000 researchers and clinician-scientists from over 40 countries to explore advances across multidisciplinary neuro-oncology research, diagnosis, and treatment.

The comprehensive program featured cutting-edge scientific and poster sessions, expert-led presentations, exhibits, networking activities.

The 2026 SNO Education Day on November 12 gathered international thought leaders to highlight advances in brain tumor treatment. Sessions featured emerging diagnostics, AI, biomarkers, targeted therapies, cell-based immunotherapies, and novel CNS drug-delivery platforms – with a focus on obstacles and clinical translation.

You can also read:

Tarlatamab